Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Korean firms seek US FDA approval for new anticancer drugs and biosimilars Korean pharmaceutical companies renewed their ...

Kim Kyung-Ah, CEO of Samsung Bioepis, stated in her New Year's address on the 2nd, 'The U.S. launch of biosimilar drugs, ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

INR:1526. win fortune slots EU approves dolutegravir dispersible tablets for the treatment of pediatric patients aged ≥ 4 weeks and ≥ 3 kg Biogen acquires r ...

INR:2592. sa20 points table 2024 Kangfang Biopharma submitted its listing application to the Hong Kong Stock Exchange. R&D expenses accounted for nearly 90 ...

INR:1994. top casino in world How to build a medical insurance policy that adapts to the development of primary medical care? The National Medical Insurance A ...

For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.

and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.